Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Colorectal Neoplasms 65Stomach Neoplasms 14Colonic Neoplasms 10Rectal Neoplasms 5Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2NSCLC 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1TAS 102 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11Drug Therapy 9aflutinib 8Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NSCLC × HMPL-013 × Clear all
NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
50 enrolled
Thoracic

NSCLC

NCT02691299 2019-02-12

FALUCA

Hutchmed

Phase 3 Completed
527 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡